C07J 7/00
Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17
Official title: Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms (C07J5/00 takes precedence)
C07J7/00 (Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17) appears on 519 US grants and 439 published applications in this corpus.
Search patents in C07J- Granted patents
- 519
- Published applications
- 439
- Assignees
- 251
- Inventors
- 1,053
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 19 | 0 |
| 1977 | 17 | 0 |
| 1978 | 15 | 0 |
| 1979 | 10 | 0 |
| 1980 | 11 | 0 |
| 1981 | 15 | 0 |
| 1982 | 13 | 0 |
| 1983 | 9 | 0 |
| 1984 | 11 | 0 |
| 1985 | 10 | 0 |
| 1986 | 14 | 0 |
| 1987 | 8 | 0 |
| 1988 | 3 | 0 |
| 1989 | 5 | 0 |
| 1990 | 14 | 0 |
| 1991 | 12 | 0 |
| 1992 | 10 | 0 |
| 1993 | 12 | 0 |
| 1994 | 5 | 0 |
| 1995 | 11 | 0 |
| 1996 | 11 | 0 |
| 1997 | 10 | 0 |
| 1998 | 11 | 0 |
| 1999 | 7 | 0 |
| 2000 | 9 | 0 |
| 2001 | 12 | 0 |
| 2002 | 6 | 8 |
| 2003 | 5 | 8 |
| 2004 | 4 | 14 |
| 2005 | 4 | 7 |
| 2006 | 7 | 11 |
| 2007 | 6 | 9 |
| 2008 | 4 | 1 |
| 2009 | 0 | 11 |
| 2010 | 2 | 5 |
| 2011 | 2 | 10 |
| 2012 | 5 | 7 |
| 2013 | 8 | 19 |
| 2014 | 8 | 23 |
| 2015 | 6 | 16 |
| 2016 | 18 | 26 |
| 2017 | 20 | 33 |
| 2018 | 14 | 20 |
| 2019 | 25 | 29 |
| 2020 | 14 | 25 |
| 2021 | 14 | 38 |
| 2022 | 19 | 26 |
| 2023 | 14 | 26 |
| 2024 | 16 | 28 |
| 2025 | 10 | 23 |
| 2026 | 4 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders21 Jul 2026US 12,686,700 B2Sage Therapeutics, Inc.
- C17, C20, and C21 substituted neuroactive steroids and their methods of use16 Jun 2026US 12,655,175 B2Sage Therapeutics, Inc.
- 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders24 Mar 2026US 12,583,884 B2Aelis Farma
- Compositions and methods for treating CNS disorders27 Jan 2026US 12,534,495 B2Sage Therapeutics, Inc.
- Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders30 Dec 2025US 12,509,487 B2The Texas A&M University System
- Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders8 Oct 2026US 2026/0308198 A1Sage Therapeutics, Inc.
- Lymph directing prodrugs24 Sep 2026US 2026/0284004 A1Monash University
- Neurosteroids and Prodrugs Thereof24 Sep 2026US 2026/0285897 A1Emory University
- Dexamethasone prodrug compositions and uses thereof20 Aug 2026US 2026/0240776 A1Ripple Therapeutics Corporation
- Regio-controllable [2+2] benzannulation with two adjacent c(sp3)-h bonds20 Aug 2026US 2026/0242341 A1The Scripps Research Institute
Most cited
By later US patents
- Orally administrable form of progesterone127US 4,196,188 A1980
- Estrogenic compounds as anti-angiogenic agents112US 5,504,074 AChildren's Medical Center Corporation · 1996
- Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series74US 5,939,545 ACoCensys, Inc. · 1999
- Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series70US 5,232,917 AUniversity of Southern California · 1993
- Anti-angiogenic agents66US 6,271,220 B1Allergan Sales, Inc. · 2001